110859-47-7

Basic information

• Product Name: (4-BENZYL-1,4-OXAZINAN-2-YL)METHYLAMINE
• Synonyms: BUTTPARK 85\12-11;C-(4-BENZYL-MORPHOLIN-2-YL)-METHYLAMINE;(4-BENZYL-1,4-OXAZINAN-2-YL)METHYLAMINE;(4-BENZYLMORPHOLIN-2-YL) METHANAMINE;(4-BENZYLMORPHOLIN-2-YL)METHYLAMINE;(4-Benzyl-1,4-oxazinan-2-yl)methylamine 90%;(4-Benzyl-1,4-oxazinan-2-yl)methylamine90%;4-Benzyl-2-(aMinoMethyl)Morpholine
• CAS NO: 110859-47-7
• Molecular Formula: C₁₂H₁₈N₂O
• Molecular Weight: 206.28
• Product Categories: pharmacetical;Aminomethyl's;Morpholines & Thiomorpholines;Morpholines & Thiomorpholines
• Mol File: 110859-47-7.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 120-122°C 0,5mm
• Flash Point: 143℃
• Appearance: /
• Density: 1.076
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.55
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 9.37±0.29(Predicted)
• CAS DataBase Reference: (4-BENZYL-1,4-OXAZINAN-2-YL)METHYLAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: (4-BENZYL-1,4-OXAZINAN-2-YL)METHYLAMINE(110859-47-7)
• EPA Substance Registry System: (4-BENZYL-1,4-OXAZINAN-2-YL)METHYLAMINE(110859-47-7)

Safety Data

• Hazard Codes: Xi
• Statements: 34
• Safety Statements: 26-36/37/39
• RIDADR: 2735
• Hazardous Substances Data: 110859-47-7(Hazardous Substances Data)

Usage

General Description

(4-Benzyl-1,4-oxazinan-2-yl)methylamine, also known as benzyl-(2-oxo-1,4-oxazinan-2-yl)methylamine, is a chemical compound with the molecular formula C16H20N2O. It is a member of the oxazinanamines class of compounds, which are organic compounds containing an oxazinane structure, a six-membered ring with three carbon atoms, one nitrogen atom, and one oxygen atom. The compound contains a benzyl group and a methylamine group, and it may have potential applications in pharmaceutical and chemical research due to its unique structure and properties. Further studies on this compound may reveal its potential uses and properties in various fields.

InChI:InChI=1/C12H18N2O/c13-8-12-10-14(6-7-15-12)9-11-4-2-1-3-5-11/h1-5,12H,6-10,13H2

Upstream product

• 100-52-7 benzaldehyde 
• 1030837-46-7 3-(benzyl(2-hydroxyethyl)amino)-2-chloro-propanenitrile 
• 79-37-8 oxalyl dichloride 
• 259538-37-9 4-benzyl-(2R)-5-oxo-2-morpholinecarboxylic acid 
• 104-63-2 N-Benzylethanolamine 
• 147767-51-9 4-benzyl-2-cyanomorpholine 
• 40987-25-5 N-benzyl-2-chloromethylmorpholine 
• 110859-48-8 N-[(4-benzyl-2-morpholinyl)methyl]phthalimide 
• 112913-97-0 2-(azidomethyl)-4-benzylmorpholine 
• 112913-96-9 2-(N-acetylaminomethyl)-4-benzylmorpholine 

Downstream Products

• 112885-38-8 N-<(4-benzyl-2-morpholinyl)methyl>-3,4-(methylenedioxy)benzamide 
• 126645-61-2 N-(4-Benzyl-morpholin-2-ylmethyl)-2,3,4,5,6-pentafluoro-benzamide 
• 112885-48-0 4-Acetylamino-N-(4-benzyl-morpholin-2-ylmethyl)-2-methoxy-benzamide 
• 112887-18-0 N-(4-Benzyl-morpholin-2-ylmethyl)-2-chloro-5-sulfamoyl-benzamide 
• 112885-58-2 N-(4-Benzyl-morpholin-2-ylmethyl)-5-chloro-2-methoxy-4-methylamino-benzamide 
• 112885-33-3 4-amino-N-<(4-benzyl-2-morpholinyl)methyl>-5-chloro-2-ethoxybenzamide 
• 112885-53-7 N-(4-Benzyl-morpholin-2-ylmethyl)-5-chloro-4-diethylamino-2-methoxy-benzamide 
• 170798-69-3 2-(benzoylamino)-N-<(4-benzyl-2-morpholinyl)methyl>-4-(dimethylamino)-5-nitrobenzamide 
• 186293-55-0 (S)-(4-benzylmorpholin-2-yl)methanamine 
• 471254-18-9 N-(4-benzyl-morpholin-2-ylmethyl)-4-hydroxy-benzamide 
• 1065678-06-9 1-(2,3-dihydro[1,4]dioxino[2,3-c]pyridin-7-yl)-N-{[4-(phenylmethyl)-2-morpholinyl]methyl}methanamine 
• 1280665-67-9 N-[(4-benzylmorpholin-2-yl)methyl]-7-[[(7R)-8-cyclopentyl-7-ethyl-5-methyl-6-oxo-7H-pteridin-2-yl]amino]-2,3-dihydrobenzofuran-4-carboxamide 
• 214273-17-3 [(2R)-4-benzylmorpholin-2-yl]methanamine 
• 173341-02-1 N-(morpholin-2-ylmethyl)carbamic acid tert-butyl ester 

Relevant articles and documents

INDAZOLE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS

The present invention relates to novel indazole compounds of the Formula (I), wherein, R1 is alkyl or cycloalkyl; (Formula II) including their stereoisomers and their pharmaceutically acceptable salts. This invention also relates to methods of making such compounds and pharmaceutical compositions comprising such compounds. The compounds of this invention are useful in the treatment of various disorders that are related to 5-Hydroxytryptamine 4 (5-HT4) receptor agonists

DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF

Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.

Discovery of triazolopyrimidine-based PDE8B inhibitors: Exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes

PDE8B is a cAMP-specific isoform of the broader class of phosphodiesterases (PDEs). As no selective PDE8B inhibitors had been reported, a high throughput screen was run with the goal of identifying selective tools for exploring the potential therapeutic utility of PDE8B inhibition. Of the numerous hits, one was particularly attractive since it was amenable to rapid deconstruction leading to inhibitors with very high ligand efficiency (LE) and lipophilic ligand efficiency (LLE). These triazolopyrimidines were optimized for potency, selectivity and ADME properties ultimately leading to compound 42. This compound was highly potent and selective with good bioavailability and advanced into pre-clinical development.